Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

75.0%

3 terminated/withdrawn out of 4 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 1
2(50.0%)
4Total
N/A(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02232477Not ApplicableTerminated

Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in MPS I

Role: collaborator

NCT00852358Not ApplicableCompleted

A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I

Role: collaborator

NCT00215527Phase 1Terminated

Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I

Role: collaborator

NCT00786968Phase 1Terminated

Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I

Role: collaborator

All 4 trials loaded